Skip to content
value.today

Cingulate Inc.: peers

Change the peers

Cingulate Inc. beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.

Climb Bio, Inc., Kyntra Bio, Inc.: the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.

Side by side#

Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.

Cingulate Inc., Neumora Therapeutics, Inc., Tenax Therapeutics, Inc., Climb Bio, Inc., Kyntra Bio, Inc., Nutriband Inc., Telomir Pharmaceuticals, Inc., Rallybio Corporation side by side: each figure with its period and source, its rank among these companies and its percentile in the company's sector and country
MeasureCingulate Inc.base
CING · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Neumora Therapeutics, Inc.
NMRA · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Tenax Therapeutics, Inc.
TENX · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Climb Bio, Inc.
CLYM · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Kyntra Bio, Inc.
KYNB · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Nutriband Inc.
NTRB · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Telomir Pharmaceuticals, Inc.
TELO · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Rallybio Corporation
RLYB · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Group median
Size
Market cap (Better neither way: ranked highest first)$83 MOct 28, 2026 · Market data4th of 8$81 MOct 16, 2026 · Market data5th of 8$86 MOct 29, 2026 · Market data3rd of 8$80 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one6th of 8$79 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one7th of 8$79 MOct 29, 2026 · Market data8th of 8$88 MOct 7, 2026 · Market data1st of 8$88 MOct 27, 2026 · Market data2nd of 8$82 M8 ranked
Revenue (Better neither way: ranked highest first)————————$6 MFY2025 · SEC1st of 3$2 MFY2025 · SEC2nd of 3——$1 MFY2025 · SEC3rd of 3$2 M3 ranked
Net income (Higher is better)$-22 MFY2025 · SEC5th of 8$-237 MFY2025 · SEC8th of 8$-53 MFY2025 · SEC6th of 8$-60 MFY2025 · SEC7th of 8$183 MFY2025 · SEC1st of 8$-8 MFY2025 · SEC2nd of 8$-10 MFY2025 · SEC4th of 8$-9 MFY2025 · SEC3rd of 8$-16 M8 ranked
Employees (Better neither way: ranked highest first)————14December 31, 2025 · Profile3rd of 428December 31, 2025 · Profile2nd of 4566As on 2021 · Profile1st of 4————14December 31, 2025 · Profile3rd of 4214 ranked
Growth
Revenue growth (Higher is better)————————————————-78.3%FY2025 · SEC2nd of 21st0th-4.7%FY2025 · SEC1st of 218th18th————————-41.5%2 ranked
Revenue growth, 3 years a year (Higher is better)————————————————-64.2%FY2025 · SEC2nd of 20th0th-0.7%FY2025 · SEC1st of 225th30th————————-32.4%2 ranked
Margins and returns
Gross margin (Higher is better)————————————————91.3%FY2025 · SEC1st of 293rd97th27.9%FY2025 · SEC2nd of 214th31st————————59.6%2 ranked
Operating margin (Higher is better)————————————————-712.7%FY2025 · SEC2nd of 23rd1st-407.8%FY2025 · SEC1st of 28th3rd————————-560.3%2 ranked
Net margin (Higher is better)————————————————————-403.4%FY2025 · SEConly one with it8th3rd————————-403.4%—
Free cash flow margin (Higher is better)————————————————-74.7%FY2025 · SEC1st of 224th10th-252.0%FY2025 · SEC2nd of 213th4th————————-163.3%2 ranked
Return on equity (Higher is better)-450.4%FY2025 · SEC7th of 72nd1st-121.2%FY2025 · SEC4th of 720th9th-55.6%FY2025 · SEC3rd of 740th17th-32.1%FY2025 · SEC2nd of 753rd23rd————-125.5%FY2025 · SEC5th of 719th8th-317.9%FY2025 · SEC6th of 74th2nd-15.0%FY2025 · SEC1st of 763rd30th-121.2%7 ranked
Valuation
Price to sales (Better neither way: ranked highest first)————————————————————48.7×price Oct 29, 2026 · Market data2nd of 291st97th————102.8×price Oct 27, 2026 · Market data1st of 295th98th75.7×2 ranked
Price to book (Better neither way: ranked highest first)33.0×price Oct 28, 2026 · Market data1st of 695th97th0.8×price Oct 16, 2026 · Market data6th of 615th14th0.9×price Oct 29, 2026 · Market data5th of 617th17th————————11.8×price Oct 29, 2026 · Market data3rd of 687th91st15.0×price Oct 7, 2026 · Market data2nd of 690th94th1.5×price Oct 27, 2026 · Market data4th of 631st37th6.7×6 ranked
Free cash flow yield (Higher is better)-21.0%price Oct 28, 2026 · Market data3rd of 432nd14th————-13.3%price Oct 29, 2026 · Market data2nd of 438th18th————————-6.5%price Oct 29, 2026 · Market data1st of 450th25th————-55.8%price Oct 27, 2026 · Market data4th of 417th7th-17.2%4 ranked
Financial strength
Debt to equity (Lower is better)————0.5×FY2025 · SEConly one with it54th46th————————————————————————0.5×—
Interest cover (Higher is better)-22.2×FY2025 · SEC2nd of 431st15th-120.0×FY2025 · SEC3rd of 413th5th————————-5.2×FY2025 · SEC1st of 454th29th-416.0×FY2025 · SEC4th of 47th2nd————————-71.1×4 ranked
Scorecard
Scorecard (Higher is better)1 of 13FY2025 · Scorecard8th of 84 of 12FY2025 · Scorecard2nd of 82 of 12FY2025 · Scorecard4th of 81 of 8FY2025 · Scorecard6th of 85 of 14FY2025 · Scorecard1st of 83 of 21FY2025 · Scorecard5th of 81 of 9FY2025 · Scorecard7th of 84 of 12FY2025 · Scorecard2nd of 815% passed8 ranked
Valuation checks (Higher is better)0 of 4FY2025 · Scorecard4th of 61 of 3FY2025 · Scorecard1st of 61 of 4FY2025 · Scorecard3rd of 6————0 of 5FY2025 · Scorecard4th of 60 of 3FY2025 · Scorecard4th of 61 of 3FY2025 · Scorecard1st of 613% passed6 ranked
Growth checks (Higher is better)0 of 2FY2025 · Scorecard4th of 80 of 1FY2025 · Scorecard4th of 80 of 2FY2025 · Scorecard4th of 80 of 2FY2025 · Scorecard4th of 82 of 6FY2025 · Scorecard2nd of 81 of 6FY2025 · Scorecard3rd of 80 of 1FY2025 · Scorecard4th of 81 of 2FY2025 · Scorecard1st of 80% passed8 ranked
Profitability checks (Higher is better)0 of 3FY2025 · Scorecard2nd of 80 of 2FY2025 · Scorecard2nd of 80 of 3FY2025 · Scorecard2nd of 80 of 3FY2025 · Scorecard2nd of 81 of 4FY2025 · Scorecard1st of 80 of 5FY2025 · Scorecard2nd of 80 of 2FY2025 · Scorecard2nd of 80 of 3FY2025 · Scorecard2nd of 80% passed8 ranked
Financial health checks (Higher is better)1 of 3FY2025 · Scorecard7th of 83 of 5FY2025 · Scorecard2nd of 81 of 2FY2025 · Scorecard3rd of 81 of 2FY2025 · Scorecard3rd of 81 of 3FY2025 · Scorecard7th of 82 of 4FY2025 · Scorecard3rd of 81 of 2FY2025 · Scorecard3rd of 82 of 3FY2025 · Scorecard1st of 850% passed8 ranked
Shareholder returns checks (Higher is better)0 of 1FY2025 · Scorecard2nd of 80 of 1FY2025 · Scorecard2nd of 80 of 1FY2025 · Scorecard2nd of 80 of 1FY2025 · Scorecard2nd of 81 of 1FY2025 · Scorecard1st of 80 of 1FY2025 · Scorecard2nd of 80 of 1FY2025 · Scorecard2nd of 80 of 1FY2025 · Scorecard2nd of 80% passed8 ranked
Ownership
Held by institutions (Better neither way: ranked highest first)19.6%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 862.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 870.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 8110.9%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 826.3%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 83.3%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in8th of 84.4%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 868.3%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 844.2%8 ranked
Institutions holding (Better neither way: ranked highest first)412026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 81272026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 81062026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 81282026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 8352026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 8192026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in8th of 8262026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 8322026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 8388 ranked
Institutional holding, change over the quarter (Better neither way: ranked highest first)+2.4 pp2026-Q2 against 2026-Q1 · 13F3rd of 8+1.8 pp2026-Q2 against 2026-Q1 · 13F4th of 8-45.0 pp2026-Q2 against 2026-Q1 · 13F8th of 8+41.7 pp2026-Q2 against 2026-Q1 · 13F2nd of 8-0.9 pp2026-Q2 against 2026-Q1 · 13F6th of 8-0.2 pp2026-Q2 against 2026-Q1 · 13F5th of 8-2.2 pp2026-Q2 against 2026-Q1 · 13F7th of 8+88.0 pp2026-Q1 against 2025-Q4 · 13F1st of 8+0.8 pp8 ranked

Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).

Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Cingulate Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Neumora Therapeutics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Tenax Therapeutics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Climb Bio, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Kyntra Bio, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Nutriband Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Telomir Pharmaceuticals, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Rallybio Corporation: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.

Where each stands in its sector and country: Operating margin#

The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.

Operating margin: each company's figure and its percentile in its sector and its country
CompanyOperating marginIn its sectorIn its country
Cingulate Inc.———
Neumora Therapeutics, Inc.———
Tenax Therapeutics, Inc.———
Climb Bio, Inc.———
Kyntra Bio, Inc.-712.7%FY2025
3rd percentile in Healthcaremedian -7.7%, 674 companies
1st percentile in USAmedian 3.5%, 2,594 companies
Nutriband Inc.-407.8%FY2025
8th percentile in Healthcaremedian -7.7%, 674 companies
3rd percentile in USAmedian 3.5%, 2,594 companies
Telomir Pharmaceuticals, Inc.———
Rallybio Corporation———

Revenue by fiscal year, and the rank in the group#

Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).

Revenue

$0 M$64 M$128 M$192 M$257 M20122014201620182020202220242026Tenax Therapeutics, Inc. $0 MKyntra Bio, Inc. $6 MNutriband Inc. $2 MRallybio Corporation $1 M

Rank in the group

1st2nd3rd2013201420182019202020212022202320242025Tenax Therapeutics, Inc.: 2nd of 2 in 2013Tenax Therapeutics, Inc.: 2nd of 2 in 2014Tenax Therapeutics, Inc.Kyntra Bio, Inc.: 1st of 2 in 2013Kyntra Bio, Inc.: 1st of 2 in 2014Kyntra Bio, Inc.: 1st of 2 in 2018Kyntra Bio, Inc.: 1st of 2 in 2019Kyntra Bio, Inc.: 1st of 2 in 2020Kyntra Bio, Inc.: 1st of 2 in 2021Kyntra Bio, Inc.: 1st of 2 in 2022Kyntra Bio, Inc.: 1st of 2 in 2023Kyntra Bio, Inc.: 1st of 3 in 2024Kyntra Bio, Inc.: 1st of 3 in 2025Kyntra Bio, Inc.Nutriband Inc.: 2nd of 2 in 2018Nutriband Inc.: 2nd of 2 in 2019Nutriband Inc.: 2nd of 2 in 2020Nutriband Inc.: 2nd of 2 in 2021Nutriband Inc.: 2nd of 2 in 2022Nutriband Inc.: 2nd of 2 in 2023Nutriband Inc.: 2nd of 3 in 2024Nutriband Inc.: 2nd of 3 in 2025Nutriband Inc.Rallybio Corporation: 3rd of 3 in 2024Rallybio Corporation: 3rd of 3 in 2025Rallybio Corporation
Revenue by fiscal year with each company's rank in the group and the source of each figure
Fiscal yearCingulate Inc.Neumora Therapeutics, Inc.Tenax Therapeutics, Inc.Climb Bio, Inc.Kyntra Bio, Inc.Nutriband Inc.Telomir Pharmaceuticals, Inc.Rallybio Corporation
2025————$6 MSEC1st$2 MSEC2nd—$1 MSEC3rd
2024————$30 MSEC1st$2 MSEC2nd—$1 MSEC3rd
2023————$47 MSEC1st$2 MSEC2nd——
2022————$141 MSEC1st$2 MSEC2nd——
2021————$235 MSEC1st$1 MSEC2nd——
2020————$176 MSEC1st$1 MSEC2nd——
2019————$257 MSEC1st$0 MSEC2nd——
2018————$213 MSEC1st$0 MSEC2nd——
2017————$131 MSEC———
2016————$183 MSEC———
2015————$181 MSEC———
2014——$0 MSEC2nd—$138 MSEC1st———

Key: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.

Suggested peers of Cingulate Inc.#

Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.

  • Neumora Therapeutics, Inc.NMRA · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $81 M market cap against $83 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $81 M (Oct 16, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Tenax Therapeutics, Inc.TENX · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $86 M market cap against $83 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $86 M (Oct 29, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Climb Bio, Inc.CLYM · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $80 M market cap against $83 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $80 M (last known, Jan 5, 2024)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Kyntra Bio, Inc.KYNB · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $79 M market cap against $83 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $79 M (last known, Jan 5, 2024) · revenue $6 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Nutriband Inc.NTRB · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $79 M market cap against $83 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $79 M (Oct 29, 2026) · revenue $2 M (year to January 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Telomir Pharmaceuticals, Inc.TELO · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $88 M market cap against $83 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $88 M (Oct 7, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Rallybio CorporationRLYB · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $88 M market cap against $83 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $88 M (Oct 27, 2026) · revenue $1 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    In the group
  • Acrivon Therapeutics, Inc.ACRV · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $77 M market cap against $83 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $77 M (Oct 21, 2026)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add
  • NeOnc Technologies Holdings, Inc.NTHI · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $90 M market cap against $83 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $90 M (Oct 30, 2026) · revenue $0 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add
  • Verrica Pharmaceuticals Inc.VRCA · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $76 M market cap against $83 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $76 M (Sep 21, 2026) · revenue $36 M (year to December 2025)
    100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)
    + Add
  • Tenaya Therapeutics, Inc.TNYA · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $91 M market cap against $83 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $91 M (Oct 28, 2026)
    99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)
    + Add
  • Coya Therapeutics, Inc.COYA · 🇺🇸 USA
    Same industry: Biotechnology · Similar size: $92 M market cap against $83 M · Same country: USA · Ratios of the last two fiscal years on file
    Market cap $92 M (Oct 26, 2026) · revenue $8 M (year to December 2025)
    99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)
    + Add

Any figure over the years, other peers or a saved group: open this group in the peer workspace.